Immunic, Inc.’s subsidiary, Immunic AG, has exercised its exclusive global option to license a group of compounds, designated as IMU-856, under the terms of its existing option and license agreement with Daiichi Sankyo Co., Ltd.   IMU-856 is an orally available, small molecule modulator that targets an undisclosed protein which serves as a transcriptional regulator of the intestinal barrier function, and represents a new and potentially disruptive approach for the treatment of intestinal disea...